In a retrospective analysis, some patients with melanoma who responded to anti–PD-1 therapy exhibited high numbers of cDC2s and low numbers of cDC1s, suggesting the possibility that the cDC2 compartment may also contribute to clinical response to ICIs.56 Here, PDCD1 is linked to melanoma.